Details for Patent: 7,727,993
✉ Email this page to a colleague
Which drugs does patent 7,727,993 protect, and when does it expire?
Patent 7,727,993 protects NOURIANZ and is included in one NDA.
This patent has thirty-six patent family members in fifteen countries.
Summary for Patent: 7,727,993
| Title: | Administering adenosine A.sub.2A receptor antagonist to reduce or suppress side effects of parkinson's disease therapy |
| Abstract: | The present invention is directed to methods of treating movement disorders by administering an effective amount of one or more adenosine A.sub.2A receptor antagonists to a patient in need thereof. The present invention also provides methods of decreasing the adverse effects of L-DOPA in patients receiving L-DOPA therapy in the treatment of Parkinson's disease. The present invention further provides methods and compositions for treating Parkinson's disease patients with sub-clinically effective doses of L-DOPA by combining L-DOPA treatment with an effective amount of one or more adenosine A.sub.2A receptor antagonists (i.e., L-DOPA sparing effect). The present invention further provides methods of effective treatment of Parkinson's disease by co-administering at least one adenosine A.sub.2A receptor antagonist, L-DOPA and a dopamine agonist and/or a COMT inhibitor and/or a MAO inhibitor. The present invention further provides methods of prolonging effective treatment of Parkinson's disease by administering an adenosine A.sub.2A receptor antagonist singly or together with a dopamine agonist, and/or a COMT inhibitor, and/or a MAO inhibitor without prior or subsequent administration of L-DOPA, delaying or removing on-set of L-DOPA motor complication. |
| Inventor(s): | Kase; Hiroshi (Tokyo, JP), Mori; Akihisa (Chiba, JP), Waki; Yutaka (Princeton, NJ), Ohsawa; Yutaka (London, GB), Karasawa; Akira (Shizuoka, JP), Kuwana; Yoshihisa (Shizuoka, JP) |
| Assignee: | Kyowa Hakko Kirin Co., Ltd. (Tokyo, JP) |
| Application Number: | 11/326,414 |
|
Patent Claim Types: see list of patent claims | Use; |
Drugs Protected by US Patent 7,727,993
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Kyowa Kirin | NOURIANZ | istradefylline | TABLET;ORAL | 022075-001 | Aug 27, 2019 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | A METHOD OF REDUCING OFF TIME FROM L-DOPA THERAPY, COMPRISING ADMINISTERING, TO A HUMAN PATIENT WITH PARKINSON'S DISEASE, AN EFFECTIVE AMOUNT OF ISTRADEFYLLINE, WHEREIN THE PATIENT CURRENTLY RECEIVES SAID L-DOPA THERAPY | ⤷ Sign Up | |||
| Kyowa Kirin | NOURIANZ | istradefylline | TABLET;ORAL | 022075-002 | Aug 27, 2019 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | A METHOD OF REDUCING OFF TIME FROM L-DOPA THERAPY, COMPRISING ADMINISTERING, TO A HUMAN PATIENT WITH PARKINSON'S DISEASE, AN EFFECTIVE AMOUNT OF ISTRADEFYLLINE, WHEREIN THE PATIENT CURRENTLY RECEIVES SAID L-DOPA THERAPY | ⤷ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 7,727,993
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Australia | 2003207734 | ⤷ Sign Up | |||
| Australia | 2008200611 | ⤷ Sign Up | |||
| Brazil | 0306919 | ⤷ Sign Up | |||
| Canada | 2473864 | ⤷ Sign Up | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
